Matters of legal in nature including licensing, intellectual property, and lawsuits.
FRANKLIN LAKES, N.J., Oct. 22, 2020 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Patrick Kaltenbach as executive vice president and chief technology officer, and the promotion of Dave Hickey to executive vice president and president, Life Sciences segment, both effective January 1, 2021.... Read more
MILAN (Italy) and MADISON (Wis., USA) – October 6, 2020 – Axxam S.p.A., a leading provider of integrated drug discovery services across life sciences industries, and FUJIFILM Cellular Dynamics, Inc., a leading developer and manufacturer of human induced pluripotent stem cell (hiPSC) models and therapies, announce a strategic alliance to improve the drug discovery process.... Read more
Exploratory efficacy data showed 88% of infants treated with Evrysdi were alive and did not require permanent ventilation at two years 59% of infants were able to sit without support for at least 5 seconds No new safety signals were identified In August, the FDA approved Evrysdi for the treatment of SMA in adults and... Read more
SAFE AND RELIABLE SAMPLE PRESERVATION AT AMBIENT TEMPERATURE FOR IVD APPLICATIONS Zymo Research was granted the CE IVD mark for its DNA/RNA Shield™ reagent and collection devices. IRVINE, Calif., (Sept. 25, 2020) — Zymo Research announced that three of its DNA/RNA Shield™ collection devices: 1) DNA/RNA Shield™ collection tube w/ swab, 2) DNA/RNA Shield™ Saliva/Sputum Collection Kit, and 3) DNA/RNA Shield™ Fecal Collection... Read more
NGS-enabled platform tracks infection clusters for contact tracing and monitors emerging mutations, combining once separate aspects of screening and genomic surveillance SAN CARLOS, CALIF. (PRWEB) SEPTEMBER 24, 2020 Clear Labs, providers of the only fully automated and intelligent next-generation sequencing (NGS) in vitro diagnostic (IVD) platform, today announced that the U.S. Food and Drug Administration (FDA) has... Read more
AUSTIN, Texas, Sept. 23, 2020 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that it has received an award of $683,500 from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, to support the enhancement of... Read more
Data from the Phase III IMpassion031 study demonstrated that Tecentriq in combination with chemotherapy improved pathological complete response for patients with early triple-negative breast cancer (TNBC), when compared to placebo plus chemotherapy Final overall survival data from the Phase III IMpassion130 study were consistent with prior interim analyses in patients with metastatic TNBC, whose tumours... Read more
New and updated data from across our broad cancer portfolio including phase III results in breast, lung and prostate cancers New integrated analyses from our tumour agnostic Rozlytrek® (entrectinib) clinical development programme Blueprint Medicines will present new data from the registrational phase I/II ARROW trial, investigating GavretoTM(pralsetinib) for the treatment of people with RET-mutant medullary... Read more
75% of patients with relapsing-remitting multiple sclerosis (RRMS) and suboptimal response to prior treatment had no evidence of disease activity two years after switching to OCREVUS in open-label Phase IIIb CASTING study 97% persistence and strong adherence to OCREVUS treatment and twice-yearly dosing schedule from real-world data OCREVUS is the first and only treatment approved... Read more
RYE BROOK, N.Y.–(BUSINESS WIRE)–Sep. 10, 2020– Xylem Inc. (NYSE: XYL), a leading global water technology company dedicated to solving the world’s most challenging water issues, announced today that its President and CEO, Patrick Decker, and Vice President of Investor Relations, Matt Latino, will participate in a virtual fireside chat hosted by RBC analyst Deane Dray... Read more